IDiyas

For the Inventor, By the Inventor

Sunnyvale, CA, United States of America

Xiaojun Huang

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 23(Granted Patents)


Location History:

  • Sunnyvale, CA (US) (2014 - 2021)
  • San Jose, CA (US) (2023)

Company Filing History:

goldMedal9 out of 262 
 
Theravance Biopharma R&d Ip, LLC
 patents

Years Active: 2014-2023

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 11780852 - Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2023-10-10),
2. 11739103 - Processes for preparing a pan-JAK inhibitor and related intermediate compounds (2023-08-29),
3. 11110095 - Pyrimidine compounds as JAK kinase inhibitors (2021-09-07),
4. 10947254 - Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2021-03-16),
5. 10494382 - Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and water (2019-12-03),
6. 10485803 - Pyrimidine compounds as JAK kinase inhibitors (2019-11-26),
7. 10072026 - Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2018-09-11),
8. 8921372 - Inhibitors of hepatitis C virus (2014-12-30),
9. 8883135 - Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor (2014-11-11),

Title: Innovations by Inventor Xiaojun Huang

Introduction

Xiaojun Huang is a prominent inventor based in Sunnyvale, CA, known for his significant contributions to the field of pharmaceuticals. He holds a total of nine patents, showcasing his innovative approach to medical treatments.

Latest Patents

Among his latest patents, Xiaojun Huang has developed methods for treating Crohn's disease using a specific compound formula. This compound, or its pharmaceutically-acceptable salt, is aimed at providing effective treatment options for patients suffering from this condition. Additionally, he has disclosed processes for preparing a pan-JAK inhibitor and related intermediate compounds, which include a crystalline form of the same compound used for Crohn's disease treatment.

Career Highlights

Xiaojun Huang is currently employed at Theravance Biopharma R&D IP, LLC, where he continues to push the boundaries of pharmaceutical research and development. His work is instrumental in advancing therapeutic options for various diseases.

Collaborations

He collaborates with notable colleagues, including Venkat R Thalladi and Ryan Hudson, contributing to a dynamic research environment that fosters innovation.

Conclusion

Xiaojun Huang's work exemplifies the spirit of innovation in the pharmaceutical industry, with his patents paving the way for new treatment methodologies. His contributions are vital in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…